BIOSIM Act

United States117th CongressHR-2815House of Representatives
Updated: Apr 23, 2021

Summary

Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

  1. Referred to the Subcommittee on Social Security.

    House of Representatives

  2. Referred to the Subcommittee on Health.

    House of Representatives

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  4. Referred to the Subcommittee on Health.

    House of Representatives